Peter Morris

Medicine & Life Sciences

1. Child 100%
2. Otitis Media 93%
3. Bronchiectasis 65%
4. Randomized Controlled Trials 61%
5. Conjugate Vaccines 46%
6. Northern Territory 45%
7. Suppurative Otitis Media 43%
8. Azithromycin 36%
9. Haemophilus influenzae 36%
10. Streptococcus pneumoniae 35%
11. Anti-Bacterial Agents 33%
12. Cough 32%
13. Pneumococcal Vaccines 31%
14. Haemophilus influenzae glpQ protein 26%
15. Ear 25%
16. Bronchiolitis 25%
17. Serogroup 22%
18. Placebos 21%
19. 13-valent pneumococcal vaccine 20%
20. Middle Ear 19%
21. Lung Diseases 18%
22. Vaccines 18%
23. Otitis Media with Effusion 18%
24. Respiratory Tract Infections 17%
25. Health 15%
26. Nasopharynx 14%
27. Tympanic Membrane Perforation 13%
28. Appointments and Schedules 13%
29. Nose 13%
30. Vaccination 13%
31. New Zealand 13%
32. Amoxicillin 13%
33. Population 12%
34. PHiD-CV vaccine 12%
35. Pneumonia 12%
36. Moraxella catarrhalis 11%
37. Ear Diseases 11%
38. Hearing Loss 11%
39. Local Anti-Infective Agents 11%
40. Fibrosis 10%
41. Population Groups 10%
42. Microbiology 10%
43. Hospitalized Child 9%
44. Pediatrics 9%
45. Vulnerable Populations 9%
46. Confidence Intervals 9%
47. Bacteria 9%
48. Therapeutics 9%
49. Systematic Reviews 9%
50. Minority Groups 8%